Latest Breaking News On - Williamh collier - Page 1 : comparemela.com

Arbutus to Participate in Three Upcoming Investor Conferences

06.02.2023 - WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral .

Lisam caperelliWilliamh collierArbutus biopharma corporation nasdaqHealth care conferenceAnnual health care conferenceFormal presentationBay summitBiopharma corporation

Arbutus Announces Resignation of Board Member

WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging.

Lisam caperelliWilliamh collierArbutus biopharma corporation nasdaqCompany board of directorsHuman resources committeeSecurities exchangeBiopharma corporationTram tranArbutus boardExecutive compensationHuman resourcesLooking statementsSecurities actSecurities exchange actArbutu annual reportArbutu quarterly reports

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGaston picchioLisam caperelliN acetylgalactosamine galnacWilliamh collierArbutus biopharma corporation nasdaqArbutus biopharma corporationWorld health organizationSecurities exchangeBiopharma corporationChief development officerLooking statementsSecurities actSecurities exchange actArbutu annual reportArbutu quarterly reports

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update - read this article along with other careers information, tips and advice on BioSpace

United kingdomUnited statesLisam caperelliWilliam collierN acetylgalactosamine galnacWilliamh collierRoivant sciences ltdAssembly biosciences incWorld health organizationWhile the companyArbutus biopharma corporation nasdaqUniversity of british columbiaSecurities exchangeQilu pharmaceutical co ltdBiopharma corporationArbutu president

Arbutus to Present at Jefferies London Healthcare Conference

08.11.2022 - WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral .

Lisam caperelliWilliamh collierArbutus biopharma corporation nasdaqBiopharma corporation